Clinical Trials Directory

Trials / Completed

CompletedNCT00496015

Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A

Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Vaccine GSK1024850A and DTPa-HBV-IPV/Hib Vaccine (Infanrix Hexa) and Assessment of Impact of Pneumococcal Vaccination on Nasopharyngeal Carriage

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
750 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
12 Months – 15 Months
Healthy volunteers
Accepted

Summary

The purpose of this trial is to assess if the rate of febrile reactions following the co-administration of a booster dose of pneumococcal conjugate vaccines with standard infant vaccines is lowered when paracetamol is given prophylactically and to assess the impact of pneumococcal conjugate vaccine on pneumococcal and H. influenzae nasopharyngeal carriage compared to control group receiving meningococcal conjugate vaccine (GSK134612). This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00370318).

Detailed description

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Conditions

Interventions

TypeNameDescription
BIOLOGICALPneumococcal conjugate vaccine GSK1024850A.1 intramuscular injection.
BIOLOGICALInfanrix hexa.1 intramuscular injection.
BIOLOGICALMeningococcal vaccine GSK134612.1 intramuscular injection.
DRUGParacetamol.Body weight of \< 7 kg: none; Body weight of ≥ 7 kg to \< 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.

Timeline

Start date
2007-07-02
Primary completion
2008-03-25
Completion
2009-02-17
First posted
2007-07-04
Last updated
2019-01-18
Results posted
2019-01-18

Locations

10 sites across 1 country: Czechia

Source: ClinicalTrials.gov record NCT00496015. Inclusion in this directory is not an endorsement.